{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:02:04Z","timestamp":1791313324075,"version":"4.3.1"},"reference-count":30,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have advanced the treatment of type 2 diabetes mellitus (T2DM), yet their association with cancer risk remains subject of ongoing research. Chronic pancreatitis (CP) is a well-established risk factor for pancreatic cancer, yet the impact of GLP-1 RA therapy in this high-risk population is unknown. In this study, we aimed to evaluate the association between GLP-1 RA use and pancreatic cancer incidence among patients with CP, and among those with CP and T2DM. Methods: We performed a retrospective cohort study using data from TriNetX, a healthcare database of over 150 million patients in the United States. In the first analysis, adult patients with pre-existing CP were identified and stratified by use of a GLP-1 RA (semaglutide, dulaglutide, tirzepatide, exenatide, liraglutide, lixisenatide, and albiglutide). Propensity score matching (PSM) was conducted between GLP1-RA users and non-users, matching for age, sex, race, tobacco use, alcohol use, hypertension, hyperlipidemia, obesity, and pancreatic cysts. Five-year incidence of pancreatic cancer was compared between GLP-1 RA users and non-users in the matched cohort between 2015 and 2025. We then restricted the cohort to patients with CP and T2DM and repeated this analysis. Results: We identified 89,596 patients with CP, including 3183 GLP-1 RA users and 86,413 non-users. After PSM, GLP-1 RA use was associated with a lower 5-year incidence of pancreatic cancer (hazard ratio (HR) 0.49, 95% confidence interval (CI) 0.30\u20130.80, p &lt; 0.005). Similarly, amongst patients with CP and T2DM, GLP-1 RA use was associated with a lower 5-year incidence of pancreatic cancer (HR 0.53, 95% CI 0.31\u20130.91, p &lt; 0.05). Conclusions: GLP-1 RA use was associated with a significantly reduced incidence of pancreatic cancer in all patients with CP, as well as the subpopulation with both CP and T2DM. Given the elevated cancer risk in CP, these findings suggest a potential beneficial effect of GLP-1RA use in this high-risk population. Prospective studies will be important to further analyze and confirm this potential benefit.<\/jats:p>","DOI":"10.3390\/cancers18020179","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T08:42:58Z","timestamp":1767688978000},"page":"179","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Glucagon-like Peptide-1 Receptor Agonist Use and Pancreatic Cancer Risk in Patients with Chronic Pancreatitis"],"prefix":"10.3390","volume":"18","author":[{"given":"Sarina","family":"Ailawadi","sequence":"first","affiliation":[{"name":"Department of Medicine, University Hospitals, Case Western Reserve University, Cleveland, OH 44106, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer E.","family":"Murphy","sequence":"additional","affiliation":[{"name":"Department of Clinical Research Development, University Hospitals, Cleveland, OH 44106, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1266-7393","authenticated-orcid":false,"given":"Michael H.","family":"Storandt","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1111-8333","authenticated-orcid":false,"given":"Amit","family":"Mahipal","sequence":"additional","affiliation":[{"name":"Department of Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University, 11100 Euclid Ave., Cleveland, OH 44106, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40364-025-00765-3","article-title":"Glucagon-like Peptide 1 Receptor Agonists and Cancer Risk: Advancing Precision Medicine through Mechanistic Understanding and Clinical Evidence","volume":"13","author":"Lin","year":"2025","journal-title":"Biomark. Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.amjmed.2025.01.021","article-title":"Mechanisms of GLP-1 Receptor Agonist-Induced Weight Loss: A Review of Central and Peripheral Pathways in Appetite and Energy Regulation","volume":"138","author":"Moiz","year":"2025","journal-title":"Am. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Ayoub, M., Faris, C., Juranovic, T., Chela, H., and Daglilar, E. (2024). The Use of Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus Does Not Increase the Risk of Pancreatic Cancer: A U.S.-Based Cohort Study. Cancers, 16.","DOI":"10.3390\/cancers16091625"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.3748\/wjg.v28.i25.2881","article-title":"Incretin Based Therapy and Pancreatic Cancer: Realising the Reality","volume":"28","author":"Suryadevara","year":"2022","journal-title":"World J. Gastroenterol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e228","DOI":"10.37765\/ajmc.2025.89778","article-title":"Trends in Glucagon-Like Peptide 1 Receptor Agonist Prescribing Patterns","volume":"31","author":"Ukhanova","year":"2025","journal-title":"Am. J. Manag. Care."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e029282","DOI":"10.1161\/JAHA.122.029282","article-title":"Role of Glucagon-Like Peptide-1 Receptor Agonists in Achieving Weight Loss and Improving Cardiovascular Outcomes in People With Overweight and Obesity","volume":"12","author":"Michos","year":"2023","journal-title":"J. Am. Heart Assoc."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s13098-024-01497-4","article-title":"Effects of Glucagon-like Peptide-1 Receptor Agonists on Cardiovascular Outcomes in High-Risk Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"16","author":"Chen","year":"2024","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1900\/RDS.2014.11.202","article-title":"Adverse Effects of GLP-1 Receptor Agonists","volume":"11","author":"Filippatos","year":"2014","journal-title":"Rev. Diabet. Stud."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e2421305","DOI":"10.1001\/jamanetworkopen.2024.21305","article-title":"Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients with Type 2 Diabetes","volume":"7","author":"Wang","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1111\/dom.16489","article-title":"GLP-1 Receptor Agonists and the Risk for Cancer: A Meta-Analysis of Randomized Controlled Trials","volume":"27","author":"Silverii","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Zhong, Y., Wu, T., and Khan, N.U. (2025). Association between GLP-1 Receptor Agonists as a Class and Colorectal Cancer Risk: A Meta-Analysis of Retrospective Cohort Studies. BMC Gastroenterol., 25.","DOI":"10.1186\/s12876-025-04211-4"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"E2350408","DOI":"10.1001\/jamanetworkopen.2023.50408","article-title":"Glucagon-Like Peptide-1 Receptor Agonists and Pancreatic Cancer Risk in Patients with Type 2 Diabetes","volume":"7","author":"Dankner","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1136\/gut.51.6.849","article-title":"Risk of Pancreatic Adenocarcinoma in Chronic Pancreatitis","volume":"51","author":"Malka","year":"2002","journal-title":"Gut"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Le Cosquer, G., Maulat, C., Bournet, B., Cordelier, P., Buscail, E., and Buscail, L. (2023). Pancreatic Cancer in Chronic Pancreatitis: Pathogenesis and Diagnostic Approach. Cancers, 15.","DOI":"10.3390\/cancers15030761"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.hoc.2022.07.002","article-title":"Pancreatic Adenocarcinoma: Trends in Epidemiology, Risk Factors, and Outcomes","volume":"36","author":"Afghani","year":"2022","journal-title":"Hematol. Oncol. Clin. North. Am."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1053\/j.gastro.2018.05.023","article-title":"Model to Determine Risk of Pancreatic Cancer in Patients with New-Onset Diabetes","volume":"155","author":"Sharma","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/MOG.0000000000000756","article-title":"Diabetes in Chronic Pancreatitis: Risk Factors and Natural History","volume":"37","author":"Goodarzi","year":"2021","journal-title":"Curr. Opin. Gastroenterol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Oh, Y.S., and Jun, H.S. (2018). Effects of Glucagon-like Peptide-1 on Oxidative Stress and Nrf2 Signaling. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19010026"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.7150\/ijbs.27774","article-title":"GLP-1 Treatment Protects Endothelial Cells from Oxidative Stress-Induced Autophagy and Endothelial Dysfunction","volume":"14","author":"Cai","year":"2018","journal-title":"Int. J. Biol. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"49","DOI":"10.4093\/dmj.2024.0105","article-title":"Use of Glucagon-Like Peptide-1 Receptor Agonists Does Not Increase the Risk of Cancer in Patients with Type 2 Diabetes Mellitus","volume":"49","author":"Kim","year":"2025","journal-title":"Diabetes Metab. J."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Duan, X., Wang, W., Pan, Q., and Guo, L. (2021). Type 2 Diabetes Mellitus Intersects With Pancreatic Cancer Diagnosis and Development. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.730038"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Guo, H., Guo, Q., Li, Z., and Wang, Z. (2024). Association between Different GLP-1 Receptor Agonists and Acute Pancreatitis: Case Series and Real-World Pharmacovigilance Analysis. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1461398"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jamainternmed.2013.2720","article-title":"Glucagonlike Peptide 1-Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus: A Population-Based Matched Case-Control Study","volume":"173","author":"Singh","year":"2013","journal-title":"JAMA Intern. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e1289","DOI":"10.14309\/01.ajg.0000864036.15004.08","article-title":"S1849 Watch out for Semaglutide: Potential Cause of Pancreatitis?","volume":"117","author":"Patel","year":"2022","journal-title":"Am. J. Gastroenterol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Ayoub, M., Chela, H., Amin, N., Hunter, R., Anwar, J., Tahan, V., and Daglilar, E. (2025). Pancreatitis Risk Associated with GLP-1 Receptor Agonists, Considered as a Single Class, in a Comorbidity-Free Subgroup of Type 2 Diabetes Patients in the United States: A Propensity Score-Matched Analysis. J. Clin. Med., 14.","DOI":"10.3390\/jcm14030944"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s12020-020-02223-6","article-title":"GLP-1 Receptor Agonists and Pancreatic Safety Concerns in Type 2 Diabetic Patients: Data from Cardiovascular Outcome Trials","volume":"68","author":"Cao","year":"2020","journal-title":"Endocrine"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e70113","DOI":"10.1002\/edm2.70113","article-title":"Evaluating the Rates of Pancreatitis and Pancreatic Cancer Among GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomised Controlled Trials","volume":"8","author":"Wen","year":"2025","journal-title":"Endocrinol. Diabetes Metab."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Henney, A.E., Heague, M., Riley, D.R., Hydes, T.J., Anson, M., Alam, U., and Cuthbertson, D.J. (2025). Synergistic Associations of Metformin and GLP-1 Receptor Agonist Use with Adiposity-Related Cancer Incidence in People Living with Type 2 Diabetes. Diabetes Obes. Metab.","DOI":"10.1111\/dom.70267"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"20420188231222367","DOI":"10.1177\/20420188231222367","article-title":"Anti-Inflammatory Role of Glucagon-like Peptide 1 Receptor Agonists and Its Clinical Implications","volume":"15","author":"Alharbi","year":"2024","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like Peptide-1 Receptor: Mechanisms and Advances in Therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct. Target. Ther."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/2\/179\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T08:54:00Z","timestamp":1767689640000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/2\/179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["cancers18020179"],"URL":"https:\/\/doi.org\/10.3390\/cancers18020179","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,6]]}}}